id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0097-0036,FDA,FDA-2003-N-0097,Response from FDA OC to The Honorable Charles E. Grassley,Other,Response(s),2015-12-08T05:00:00Z,2015,12,,,2025-03-06T14:02:12Z,,0,0,0900006480483a6b
FDA-2003-N-0097-0032,FDA,FDA-2003-N-0097,"Attachment 2 Farrugia and Prowse Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality. J Clin Pathol 1985; 38:433-437 re: Comment from 
European Pharmacopoeia (PhEur)",Supporting & Related Material,Background Material,2015-12-08T05:00:00Z,2015,12,,,2025-03-25T15:44:33Z,,0,0,0900006480483a63
FDA-2003-N-0097-0031,FDA,FDA-2003-N-0097,Attachment 1 Åkerblom et al Freezing technique and quality of fresh-frozen plasma. Infusionstherapie 1992; 19:283-287 re: Comment from European Pharmacopoeia (PhEur),Supporting & Related Material,Background Material,2015-12-08T05:00:00Z,2015,12,,,2015-12-08T16:48:41Z,,0,0,0900006480483a61